Highlights Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Delayed Nasdaq Stockholm Other stock markets 04:57:02 15/05/2024 pm IST			5-day change	1st Jan Change
96.8 ^SEK	-2.22%		+8.76%	+7.56%

07/05	Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/02	Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	08/02	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25	CI
Infant Bacterial Therapeutics AB Announces Data Monitoring Committee Performs the Planned Safety Analysis of the Study Data of 1,403 Babies	21/23/21	CI
Infant Bacterial Therapeutics AB Continues to Recruit Precious to Its Connection Study	21/23/21	CI
Infant Bacterial Therapeutics AB Announces New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe	15/23/15	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	08/23/08	CI
Infant Bacterial Therapeutics Announces Opening of Final Infant Cohort Will Accelerate Patient Recruitment	22/23/22	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/23/10	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Infant Bacterial Therapeutics AB Publishes Clinical Findings in British Journal of Gastroenterology	24/23/24	CI
Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections	12/23/12	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
FDA Approves Infant Bacterial Therapeutics' Request for a New Orphan Drug Designation	23/22/23	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/22/25	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022	05/22/05	CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	05/22/05	CI
Infant Bacterial Therapeutics Announces the Connection Study Continues After Pre-Scheduled Data Monitoring Committee Review	20/22/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Highlights

Filters